Modi-1 Moditope

Phase 2Biologic

SScancell Ltd

Modi-1 Moditope is one of 5 biologic programs targeting Head and Neck. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and NeckRecruiting

Head and NeckPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Head and Neck

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

3 2

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Phase 3

1 3

Modi-1 Moditope

SScancell Ltd

Phase 2

1 4

E-Z-Cat Dry

BBracco Diagnostics, Inc

Ethyl Chloride

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Head and Neck

NCT05329532

Clinical

Trials by Indication[1]

Head and Neck1 trial

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Recruiting·SScancell Ltd·Phase 1/2·NCT05329532·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Modi-1 Moditope. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Modi-1 Moditope compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Modi-1 Moditope. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Scancell Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SScancell Ltd

Modi-1 Moditope

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Head and Neck1 trial

References

Drug Info

Quick Facts

Related News